An Italian Experience on Grade 3b Follicular Lymphoma

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02927717

Acronym

FL3b-Oss-2015

Enrollment

Registered

2016-10-07

Start date

2016-10-31

Completion date

2017-05-31

Last updated

2016-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Grade 3b Follicular Lymphoma

Keywords

Grade 3b Follicular Lymphoma, 2016 WHO Criteria, Front-line treatment, Rituximab

Brief summary

Study purpose is to evaluate baseline clinical data, outcome after front-line Rituximab containing chemotherapy and survival in patients with grade 3b Follicular Lymphoma. Also an histological central review is planned in order to re-assess baseline diagnosis according to new 2016 World Health Organization (WHO) criteria.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of grade 3b Follicular Lymphoma * Age \> 18 years * Front-line treatment with Rituximab containing chemotherapy * Availability of histological sample for central review

Exclusion criteria

* Other lymphoma diagnosis

Design outcomes

Primary

Measure	Time frame	Description
Overall Response Rate	End of front-line treatment (evaluated from diagnosis up to 30 months)	Number of patients who achieve Complete Response or Partial Response after treatment

Secondary

Measure	Time frame	Description
Progression Free Survival	From first response to last follow-up for at least 2 years (up to 15 years)	Time from last response to nearest relapse or follow-up
Overall Survival	Date of last follow-up for at least 2 years (up to 15 years)	Time to last follow-up or death

Contacts

Primary ContactBarbara Botto, MD

bbotto@cittadellasalute.to.it+390116334553

Outcome results